Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Acquired by Vestal Point Capital LP

Vestal Point Capital LP raised its stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 172.2% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,075,000 shares of the company's stock after buying an additional 680,000 shares during the period. Dianthus Therapeutics comprises 1.4% of Vestal Point Capital LP's holdings, making the stock its 27th biggest holding. Vestal Point Capital LP owned about 3.63% of Dianthus Therapeutics worth $23,435,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also added to or reduced their stakes in the stock. FMR LLC boosted its holdings in shares of Dianthus Therapeutics by 0.8% in the fourth quarter. FMR LLC now owns 4,439,281 shares of the company's stock valued at $96,776,000 after purchasing an additional 36,133 shares during the period. Octagon Capital Advisors LP grew its stake in Dianthus Therapeutics by 20.8% in the fourth quarter. Octagon Capital Advisors LP now owns 2,110,167 shares of the company's stock valued at $46,002,000 after purchasing an additional 363,500 shares during the last quarter. TCG Crossover Management LLC bought a new position in shares of Dianthus Therapeutics during the 4th quarter worth approximately $32,735,000. Braidwell LP boosted its position in shares of Dianthus Therapeutics by 144.4% in the 4th quarter. Braidwell LP now owns 1,206,589 shares of the company's stock worth $26,304,000 after purchasing an additional 712,902 shares in the last quarter. Finally, Alliancebernstein L.P. grew its stake in shares of Dianthus Therapeutics by 13.4% during the fourth quarter. Alliancebernstein L.P. now owns 1,159,776 shares of the company's stock worth $25,283,000 after acquiring an additional 136,633 shares during the last quarter. 47.53% of the stock is currently owned by institutional investors.

Dianthus Therapeutics Stock Down 2.1%

Shares of NASDAQ:DNTH traded down $0.39 during trading on Thursday, hitting $18.36. 210,299 shares of the stock traded hands, compared to its average volume of 273,180. The company has a fifty day moving average price of $19.25 and a two-hundred day moving average price of $21.97. Dianthus Therapeutics, Inc. has a 52-week low of $13.37 and a 52-week high of $32.27. The company has a market cap of $590.46 million, a price-to-earnings ratio of -7.34 and a beta of 1.48.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.82) earnings per share for the quarter, beating analysts' consensus estimates of ($0.86) by $0.04. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. The company had revenue of $1.16 million during the quarter, compared to analysts' expectations of $0.81 million. On average, equities research analysts predict that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on DNTH shares. Robert W. Baird reduced their price target on shares of Dianthus Therapeutics from $58.00 to $50.00 and set an "outperform" rating for the company in a research report on Tuesday, May 13th. HC Wainwright reissued a "buy" rating and set a $40.00 target price on shares of Dianthus Therapeutics in a report on Tuesday, May 13th. Wedbush restated an "outperform" rating and set a $36.00 target price on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Finally, Guggenheim reaffirmed a "buy" rating and set a $84.00 price target on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Seven analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Buy" and an average target price of $53.00.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.